Behind the Money

Moderna’s race to the vaccine

The Boston-based biotech eschewed a traditional approach to vaccine development, instead pitching its use of mRNA technology to investors. That pitch paid off this year as the company stands to be one of the first to bring a Covid-19 vaccine to market. Hannah Kuchler, the FT’s US pharma and biotech correspondent, reports on Moderna’s race to find an immunisation for the novel coronavirus.   The FT is making key coronavirus coverage free to read for everyone. Go to <a href="https://www.ft.com/coronavirusfree" rel="noopener noreferrer" target="_blank">ft.com/coronavirusfree</a> to read the latest. Read more here: <a href=" https://www.ft.com/content/0cf071a2-b6a6-49ac-b921-f3ecd30267b2" rel="noopener noreferrer" target="_blank">Moderna’s Covid vaccine offers vindication of its unconventional approach</a> Review clips: Yahoo Finance, CNBC Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer" style="color:grey;" target="_blank">acast.com/privacy</a> for more information.

From hostile takeovers to C-suite intrigue, Behind the Money takes you inside the business and financial stories of the moment with reporting from Financial Times journalists around the world. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer" style="color:grey;" target="_blank">acast.com/privacy</a> for more information.